| abstract |
The present disclosure relates to novel treatments for treating patients with inflammatory arthritis, such as rheumatoid arthritis (RA) patients, such as high-risk RA patients, using a therapeutically effective amount of an IL-17 antagonist, such as IL. A -17 binding molecule (eg, an IL-17 antibody or antigen-binding fragment thereof, such as secukinumab) or an IL-17 receptor binding molecule (eg, an IL-17 antibody or antigen-binding fragment thereof). |